Form 4: Benitec Biopharma Director Awarded Stock Options

Benitec Biopharma Director Kishan Mehta was awarded 35,000 stock options with an exercise price of $12.23, vesting by December 2026.

Summary

• Kishan Mehta, a Director of Benitec Biopharma Inc. (BNTC), was awarded 35,000 options to purchase shares of the Issuer's common stock.
• The options have an exercise price of $12.23 per share.
• The transaction date for the option grant was December 1, 2025.
• The options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.
• The options have an expiration date of December 1, 2035.
• Mr. Mehta disclaims beneficial ownership of these options, as he holds them for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd.
• Suvretta Capital Management, LLC, the investment manager of the Funds, may have an indirect pecuniary interest due to rights to receive director compensation related to Mr. Mehta's board service.

Sentiment

Score: 5

Explanation: The filing is a standard report of an insider transaction (option grant) and does not contain information that would significantly alter the company's fundamental outlook or financial performance, thus maintaining a neutral sentiment.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options have a long expiration date (December 1, 2035), providing a significant window for potential value realization.

Future Outlook

The stock options are set to vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026, indicating a future milestone for the director's equity compensation.

Industry Context

This director option grant is a standard form of executive and board compensation in the biopharmaceutical industry, aiming to align leadership incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a common practice in publicly traded companies, particularly within the biotechnology and pharmaceutical sectors, to attract and retain talent and align interests.
• The vesting schedule, tied to either an annual meeting or a specific date, is typical for such grants, ensuring continued service.

Related Party Transactions

• Kishan Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd., holds the options for the benefit of these Funds. Suvretta Capital Management, LLC, the investment manager of the Funds, may have an indirect pecuniary interest in the options due to rights to receive director compensation related to Mr. Mehta's board service.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with long-term shareholder value, potentially leading to more favorable strategic decisions.
• Management: Provides an incentive for the director to contribute to the company's growth and stock performance.

Next Steps

• The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.

Key Dates

Keywords

Benitec Biopharma, BNTC, Kishan Mehta, Stock Options, Insider Transaction, Director Compensation, SEC Form 4, Biopharma, Equity Grant